Table 4B.

Multiple regression models for flow-mediated dilatation (in %) in CKD male patients: Free testosterone

Unadjusted (β, P) (r2 = 0.20)Model 1 (β, P) (r2 = 0.21)Model 2 (β, P) (r2 = 0.69)Model 3 (β, P) (r2 = 0.74)
Free testosterone (10 pg/ml)0.45 (<0.001)0.44 (<0.001)0.19 (<0.001)0.16 (<0.001)
Age (years)0.02 (0.61)0.03 (0.34)0.02 (0.41)
BMI (kg/m2)0.09 (0.10)0.01 (0.77)0.01 (0.88)
Total cholesterol (nmol/L)0.02 (0.75)−0.04 (0.19)−0.03 (0.39)
Diabetes (presence)−0.06 (0.26)−0.10 (0.01)−0.10 (<0.001)
Previous CVD (presence)−0.01 (0.09)−0.06 (0.08)−0.06 (0.09)
Systolic BP (mmHg)−0.03 (0.57)−0.11 (0.004)−0.10 (0.01)
Diastolic BP (mmHg)−0.06 (0.32)0.02 (0.55)0.01 (0.76)
Smoking (yes/no)−0.07 (0.24)−0.06 (0.09)−0.05 (0.13)
eGFR (ml/min per 1.73 m2)0.72 (<0.001)0.48 (<0.001)
Proteinuria (g/day)−0.02 (0.53)0.01 (0.80)
CRP (mg/L)0.05 (0.30)
Albumin (g/dl)0.08 (0.03)
Serum calcium (mg/dl)0.03 (0.51)
Serum phosphate (mg/dl)0.02 (0.75)
PTH (pg/ml)−0.33 (<0.001)
  • CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; CVD, cardiovascular disease; BMI, body mass index; CRP, C-reactive protein; PTH, parathyroid hormone.